CN103965299B - A kind of ring pentapeptide and synthetic method thereof and application - Google Patents
A kind of ring pentapeptide and synthetic method thereof and application Download PDFInfo
- Publication number
- CN103965299B CN103965299B CN201410168828.8A CN201410168828A CN103965299B CN 103965299 B CN103965299 B CN 103965299B CN 201410168828 A CN201410168828 A CN 201410168828A CN 103965299 B CN103965299 B CN 103965299B
- Authority
- CN
- China
- Prior art keywords
- tertbutyloxycarbonyl
- leu
- protection
- methyl
- pentapeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Abstract
The invention belongs to organic chemical synthesis field, disclose a kind of new structure ring pentapeptide and synthetic method thereof and application.The ring pentapeptide of described new structure is ring (N methyl D phenylalanyl D leucyl N methyl D leucyl D leucyl leucyl), and molecular formula is C35H57N5O5, structural formula is as follows.This ring pentapeptide is with D leucine, L leucine, D phenylalanine and D leucine benzyl ester tosilate as raw material, tripeptide intermediate and dipeptides intermediate is prepared respectively by suitable technique, and cyclization site selects, in D, amido link position that L-configuration is adjacent, to be effectively increased cyclization efficiency.The synthesis technique of the present invention is simple, and cost of material is low, and reaction condition is gentle, and purity is high, it is easy to industrialization, can fully meet the needs of medical experiment and Clinical practice.
Description
Technical field
The invention belongs to organic chemical synthesis field, be specifically related to a kind of ring pentapeptide and synthetic method thereof and application.
Background technology
Cyclic peptide compound is widespread in nature.Plant, animal, marine organisms, microorganism, antibacterial and the disease such as low
The cyclic peptide containing trace such as bacterium, although the content of these cyclic peptide is low, but terrestrial organism when their specific structure and pharmacological action
Incomparable.Coupling reagent compounds has significant pharmacology stability and potent property, and toxicological effect is relatively small, right
The difficult miscellaneous diseases such as anti-curing cancers, acquired immune deficiency syndrome (AIDS), cardiovascular and cerebrovascular disease, senile disease have unique effect, it has also become developing new drug, specific drug
One of Main way.
Owing to cyclic peptide lacks free N end and C end, restricted conformation can be formed.In general, with corresponding linear peptides phase
Ratio, it has more preferable metabolic stability in vivo, and resistance to enzymolysis ability is higher.Many researchs are it has been proved that from straight chain
Guide structure peptide makes original biological activity improve tens times to several ten thousand times after changing cyclic peptide into.(Fairlie D.P.,
Abbenante G., March D.R., Curr.Med.Chem., 1995,2,654-686；Bruce J, Aungst and
Hirosi Saitoh, Pharmaceutical Research, 1996,13 (1), 114-119；Dae-Yeon Suh, Yong
Chul Kim, Young-Hwa Kang.J.Nat.Prod., 1997,60,265-269；Bogdanowich-Knipp S.J.,
Jois D.S.S., Siahaan T.J.J.Pept.Res., 1999,53,523-529；DermocCox, ToshiakiAoki,
JiroSeki, Yukio Motoyama, keizo YoshidaMed.Res.Rev., 1994,14 (2), 195-228.) in view of ring
The plurality of advantages of peptide, the study hotspot to polypeptide is transferred into synthesis and the biological assessment of cyclic peptide in recent years.
Galaxamide is the red algae emulsus silk joint algae that this seminar gathers from China's Xisha Islands of South China Sea Yongxing Island
In (Galaxaura filamentosa) isolated a kind of Novel ring pentapeptide (Xu W.J., Liao X.J., Xu S.H.,
Organic Letters, 2008,10 (20), 4569-4572.), anti tumor activity in vitro experiment shows that this compound is to people liver
JEG-3 HepG2And Bel-7402, MCF-7 cell strainHJ2mm, the kinds of tumor cells such as human cervical carcinoma cell lines Hela
There is certain cytotoxicity, this compound induction hepatoma carcinoma cell Bel-7402 Apoptosis mechanism carried out preliminary study simultaneously,
Result display Galaxamide is expected to become the lead compound of new type anticancer medicine, but natural origin isolated has
The preferably natural product of activity is the most a small amount of, it is impossible to meets people's needs, explores its structure activity relationship, further investigation the most further
Its pharmacological action, Galaxamide is carried out structural modification and synthesizes its analog and be particularly important.To Galaxamide class
Carry out anti tumor activity in vitro screening like thing and intermediate thereof, and compare with Galaxamide, novel anti-to developing
The lead compound of tumour medicine.
Summary of the invention
In order to solve the weak point that prior art exists, the primary and foremost purpose of the present invention is to provide a kind of ring pentapeptide.
Another object of the present invention is to provide the synthetic method of above-mentioned ring pentapeptide.
It is still another object of the present invention to provide the application in preparing cancer therapy drug of the above-mentioned ring pentapeptide.
The object of the invention is achieved through the following technical solutions:
A kind of ring pentapeptide, its chemical name is: ring (N-methyl D-phenylalanyl-D-leucyl-N-methyl D-bright ammonia
Acyl-D-leucyl-L-leucyl)；English abbreviation expression formula is: cyclo-(N-Me-D-Phe-D-Leu-N-Me-D-Leu-D-
Leu-L-Leu)；Molecular formula is C35H57N5O5；Structural formula is as follows:
The synthetic method of above-mentioned ring pentapeptide, specifically includes following synthesis step:
(1) by L-Leu, D-Leu and D-phenylalanine respectively with Bis(tert-butoxycarbonyl)oxide (Boc2O) amino is carried out
End protection reaction, obtains tertbutyloxycarbonyl-L-Leu (Boc-L-Leu-OH), tertbutyloxycarbonyl-D-Leu (Boc-D-
And tertbutyloxycarbonyl-D-phenylalanine (Boc-D-Phe-OH) Leu-OH)；
(2) tertbutyloxycarbonyl-D-Leu step (1) obtained and tertbutyloxycarbonyl-D-phenylalanine respectively with iodine
Methane carries out methylation reaction, obtains tertbutyloxycarbonyl-N-methyl D-leucine and tertbutyloxycarbonyl-N-methyl D-phenylpropyl alcohol ammonia
Acid；
(3) tertbutyloxycarbonyl-N-methyl D-leucine step (2) obtained and tertbutyloxycarbonyl-N-methyl D-benzene
Alanine carries out condensation reaction with D-Leu benzyl ester tosilate respectively, obtains tertbutyloxycarbonyl-N-methyl D-bright ammonia
Two PEPDs are protected at acyl-D-Leu benzyl ester two ends1And tertbutyloxycarbonyl-N-methyl D (Boc-N-Me-D-Leu-D-Leu-OBn)-
Two PEPDs are protected at phenylalanyl-D-Leu benzyl ester two ends2(Boc-N-Me-D-Phe-D-Leu-OBn)；
(4) two PEPDs that step (3) is obtained2After removing tertbutyloxycarbonyl protection, the tertiary butyloxycarbonyl obtained with step (1)
Base-L-Leu carries out condensation reaction and obtains tertbutyloxycarbonyl-L-leucyl-N-methyl D-phenylalanyl-D-Leu benzyl ester
Two ends protection tripeptides T (Boc-L-Leu-N-Me-D-Phe-D-Leu-OBn)；
(5) two PEPDs that step (3) is obtained1Removing tertbutyloxycarbonyl protection, tripeptides T step (4) obtained removes benzyl
Base is protected, and then both carries out condensation reaction and obtains tertbutyloxycarbonyl-L-leucyl-N-methyl D-bright ammonia of phenylalanyl-D-
Acyl-N-methyl-D-leucyl-D-Leu benzyl ester two ends protection line style pentapeptide (Boc-L-Leu-N-Me-D-Phe-D-Leu-N-
Me-D-Leu-D-Leu-OBn)；
(6) the linear pentapeptide that step (5) obtains is removed respectively tertbutyloxycarbonyl protection and benzyl protection, in mixing condensation
Carry out under the effect of reagent ring-closure reaction i.e. obtain target product ring (N-methyl D-phenylalanyl-D-leucyl-N-methyl D-
Leucyl-D-leucyl-L-leucyl) pentapeptide (cyclo-(N-Me-D-Phe-D-Leu-N-Me-D-Leu-D-Leu-L-
Leu))。
In the synthetic method of above-mentioned ring pentapeptide, the concrete operation step of the protection reaction of aminoterminal described in step (1) is:
Under nitrogen protection, in round-bottomed flask, it is sequentially added into oxolane (THF, 150mL), H2O (100mL) and 1.0mol/L NaOH
Solution (150mL), ice-water bath cooling disposably adds L-Leu (50mmol), D-Leu (50mol) or D-phenylpropyl alcohol ammonia
Acid (50mmol), stirring and dissolving is uniform, the most disposably adds Boc2O (60mol, 1.2eq), continues stirring under ice-water bath
Being slowly increased to room temperature after 10min, regulation pH is 10～10.5, is stirred overnight, and after removing solvent under reduced pressure, extracts with absolute ether,
Aqueous phase cools down under ice-water bath and is acidified to pH=2 with 1mol/L hydrochloric acid, is then extracted with ethyl acetate 3 times, merges organic facies
And wash with saturated aqueous common salt, anhydrous MgSO4Dried filtration, finally steams solvent, respectively obtains the bright ammonia of tertbutyloxycarbonyl-L-
Acid, tertbutyloxycarbonyl-D-Leu or tertbutyloxycarbonyl-D-phenylalanine.
In the synthetic method of above-mentioned ring pentapeptide, described in step (2), the concrete operation step of methylation reaction is: by tertiary fourth
Oxygen carbonyl-D-Leu or tertbutyloxycarbonyl-D-phenylalanine are dissolved in oxolane (THF, 100mL) solution, add iodine first
Alkane (5eq) and sodium hydride (3eq), react 1-2 days, and ice-water bath downhill reaction system adds ethyl acetate (100mL) and water
(20mL), removing organic solvent under reduced pressure, the aqueous solution absolute ether obtained and water wash twice, and merge aqueous phase under ice-water bath
Being acidified to pH=2～3 with hydrochloric acid, ethyl acetate extracts 3 times, merges organic facies, the most respectively with water, 5%Na2S2O3Aqueous solution
Washing with saturated aqueous common salt, anhydrous sodium sulfate is dried, and filters, solvent is evaporated off, and oil pump is dried, and respectively obtains tertbutyloxycarbonyl-N-
Methyl D-leucine or tertbutyloxycarbonyl-N-methyl D-phenylalanine.
In the synthetic method of above-mentioned ring pentapeptide, described in step (3), (4), (5), condensation reaction refers at condensation reagent 3-
In the presence of (diethoxy phosphoryl oxy)-1,2,3-phentriazine-4-ketone (DEPBT) and diisopropylethylamine (DIEA) two kinds
Treating that condensation substance carries out dehydrating condensation accordingly, its concrete operation step is: under nitrogen protection, by treating that tertbutyloxycarbonyl is protected
Condensation substance is dissolved in oxolane, is sequentially added into DEPBT (1.5eq) and DIEA (3eq), after reaction 10～15min under ice-water bath
Add benzyl protection compound, to be dissolved after with DIEA regulation pH be 7～8, be naturally warmed to room temperature, be stirred overnight, use thin layer color
After spectrum TLC detection consumption of raw materials is complete, removes solvent, silica gel column chromatography under reduced pressure, obtain condensation product；
In the synthetic method of above-mentioned ring pentapeptide, remove tertbutyloxycarbonyl protection described in step (4), (5), (6) and refer to
Volume ratio is trifluoroacetic acid (TFA) and the dichloromethane (CH of 1:42Cl2) mixed liquor in remove the tertiary fourth oxygen in thing to be taken off
Carbonyl, its concrete operation step is: the thing to be taken off that tertbutyloxycarbonyl is protected is dissolved in CH2Cl2In, nitrogen protection is lower adds benzene first
Ether (2eq), stirs under ice bath, drips TFA, after reacting 4～6 hours, removes solvent under reduced pressure, add CH2Cl2, remove under reduced pressure,
Repetitive operation removes TFA, the product of oil pump drying to obtain removing tertbutyloxycarbonyl protection for three times.
In the synthetic method of above-mentioned ring pentapeptide, remove benzyl protection described in step (5), (6) and refer to by the quality hundred of palladium
The palladium carbon hydrogenolysis reducing dividing content to be 10% removes the benzyl in thing to be taken off, and its concrete operation step is: by benzyl protection
Thing to be taken off be dissolved in ethyl acetate, add the 10%Pd/C (mass ratio) of material amount 1/3 times amount take off under nitrogen protection, sealing
Under the conditions of be passed through the hydrogen reducing that pressure is 0.1Mpa, under room temperature stirring reaction, TLC follow the tracks of, react 4～6 hours, stop being passed through
Hydrogen, filters, and reclaims Pd/C, removes solvent under reduced pressure, is dried, and i.e. obtains removing the product of benzyl protection.
In the synthetic method of above-mentioned ring pentapeptide, ring-closure reaction described in step (6) refers at O-BTA-N, N,
N', N'-tetramethylurea Tetrafluoroboric acid ester (TBTU), 2-(7-azo BTA)-N, N, N', N'-tetramethylurea hexafluoro phosphorus
Acid esters (HATU), 3-(diethoxy phosphoryl oxy)-1,2,3-phentriazine-4-ketone (DEPBT) and diisopropylethylamine
(DIEA) carrying out cyclization in the presence of, its concrete operation step is: by removing tertbutyloxycarbonyl protection and benzyl protection linear
Pentapeptide is dissolved in the THF-CH that volume ratio is 2:1:22Cl2-CH3In CN mixed solution, ambient temperature under nitrogen is protected, and is sequentially added into HATU,
DEPBT and TBTU, successive reaction 4～6 days, remove solvent under reduced pressure, use CH2Cl2Saturated NaHCO is used successively after dissolving3Aqueous solution and
Water washs, anhydrous MgSO4Be dried, concentrate, with reversed-phase HPLC (Agilent Eclipse ZORBAX SB-C18,5μM, 9.4 ×
250nm) isolated ring five peptide prod.
Above-mentioned ring pentapeptide uses mtt assay to study its anti tumor activity in vitro, its Cleaning Principle: succinum in living cells mitochondrion
Acidohydrogenase can be reduced to water-fast bluish violet crystallization first a ceremonial jade-ladle, used in libation (Formazan) exogenous MTT and be deposited in cell, and
Dead cell there is no this function.Add dimethyl sulfoxide (DMSO) and dissolve first a ceremonial jade-ladle, used in libation, at 570nm wavelength, survey its absorbance by microplate reader
Value, can reflect living cells quantity indirectly.Its concrete operation step is:
(1) inoculating cell: collect logarithmic (log) phase cell, adjusts concentration of cell suspension, connects with every hole 1000～10000 cells
Plant in 96 orifice plates, every pore volume 100 μ l (edge hole is filled with aseptic PBS)；
(2) cell is cultivated: at 5%CO2, the cell culture incubator of 37 DEG C to be hatched, dosing in morning next day, every hole adds 100 μ
The sample to be tested of l variable concentrations, if 3 multiple holes；
(3) colour generation: cultivate 72 hours, every hole adds 20 μ l MTT solution (5mg/mL prepares with PBS, pH=7.4), continues
Continuous 4h of hatching, termination is cultivated, and carefully inhales and abandons culture supernatant in hole, and every hole adds 150 μ l DMSO, and decolorization swinging table vibrates
10min, makes crystal fully dissolve；
(4) colorimetric: select 570nm wavelength, measures the absorbance in each hole in microplate reader, records result, calculates cell
Survival rate, simultaneously with the time as abscissa, light absorption value is that vertical coordinate draws cell growth curve, and tries to achieve half-inhibition concentration
(IC50)。
Above-mentioned cyclic pentapeptide compound uses the double dye method of Annexin V-FITC/PI to detect it to HepG2 cell lines
Apoptosis mode, this method can distinguish living cells, viable apoptotic cell and dead cell.Its concrete operation step is as follows:
(1) inoculating cell: collect logarithmic (log) phase cell, adjusts concentration of cell suspension, is inoculated into 1000000, every hole cell
In 6 orifice plates, every pore volume 2mL；
(2) cell is cultivated: at 5%CO2, the cell culture incubator of 37 DEG C to be hatched, dosing in morning next day, every hole adds 1mL
The sample to be tested of variable concentrations, cultivates 72 hours；
(3) collecting cell, including the cell swum in culture medium, 2000 leave the heart 5 minutes, abandon supernatant, use 1mL PBS
Resuspended sample presentation, normal components cell separates 200 μ l volumes and does not dyes；
(4) centrifugal: 1000 revs/min, 5min, abandons supernatant；
(5) resuspended: to add 200 μ l Binding Buffer buffer mixings；
(6) dyeing: adding 5 μ l Annexin V-FITC, room temperature lucifuge hatches 10 minutes；
(7) centrifugal: 1000 revs/min, 5min, abandons supernatant；
(8) resuspended: to add 200 μ l Binding Buffer buffer mixings；
(9) dyeing: add 5 μ l PI, directly use flow cytometer measurement result.
Compared with prior art, the invention have the advantages that and beneficial effect:
(1) synthesis of the ring pentapeptide of the present invention, cyclization site selects in D, amido link position that L-configuration is adjacent, it is to avoid
Containing cyclization at N-methyl nitrosourea key, thus being effectively increased cyclization efficiency, cyclization yield can reach 65.5%；
(2) the ring pentapeptide that prepared by the present invention has the advantage that purity is high, it is possible to fully meet medical experiment and Clinical practice
Needs, there is the highest medical value；
(3) the ring pentapeptide of the present invention uses lower-cost leucine and D-phenylalanine to be synthesis material, synthesis technique
Simply, reaction condition is gentle, it is easy to industrialization, has wide market prospect.
(4) activity experiment shows, compared with Galaxamide, the ring pentapeptide of the present invention has more preferable anti-tumor activity,
Normal cell and tumor cell are demonstrated preferable selectivity.
Accompanying drawing explanation
Fig. 1 is the synthetic reaction equation of the ring pentapeptide of the present invention；
Fig. 2 is the flow cytometry figure of the ring pentapeptide PX of Galaxamide and the present invention, and figure four width figures at the middle and upper levels are
The flow cytometry figure of Galaxamide, the flow cytometry figure of the ring pentapeptide PX that four width figures are the present invention of lower floor；Figure
Middle Q1 refers to mechanical damage, and Q2 is non-viable non-apoptotic cell, and Q3 is living cells, and Q4 is viable apoptotic cell；Percent in figure is medicine
Mass concentration；In figure 0,3,6,12,24 indicated concentration (unit: μ g/mL) respectively.
Detailed description of the invention
Below in conjunction with embodiment, the present invention is described in further detail, but embodiments of the present invention are not limited to this.
The equation of the synthetic reaction of the ring pentapeptide of the present invention that embodiment 1-10 is recorded is as shown in Figure 1.
Embodiment 1 synthesizes tertbutyloxycarbonyl-L-Leu (Boc-L-Leu-OH)
Under nitrogen protection, in round-bottomed flask, it is sequentially added into oxolane (THF, 150mL), H2O (100mL) and
1.0mol/L NaOH solution (150mL), ice-water bath cooling disposably adds L-Leu (50mmol, 6.55g), stirs molten
Solve uniformly, the most disposably add Boc2O (60mol, 13.40g), is slowly increased to room temperature after continuing stirring 10min under ice-water bath,
Regulation pH is 10～10.5, is stirred overnight, and after removing solvent under reduced pressure, extracts with absolute ether, and aqueous phase cools down also under ice-water bath
It is acidified to pH=2 with 1mol/L hydrochloric acid, is then extracted with ethyl acetate 3 times, merge organic facies and wash with saturated aqueous common salt, nothing
Water MgSO4Dried filtration, finally steams solvent, obtains white powder tertbutyloxycarbonyl-L-Leu, productivity 98.7%.
Embodiment 2-in-1 one-tenth tertbutyloxycarbonyl-D-Leu (Boc-D-Leu-OH)
Repeat the operation of embodiment 1, except that replace L-Leu with D-Leu, thus prepare white powder uncle
Butoxy carbonyl-D-Leu, productivity 99.2%.
Embodiment 3 synthesizes tertbutyloxycarbonyl-D-phenylalanine (Boc-D-Phe-OH)
Repeat the operation of embodiment 1, except that replace L-Leu with D-phenylalanine, thus prepare clear oil
Thing tertbutyloxycarbonyl-D-phenylalanine, productivity 98.5%.
Embodiment 4 synthesizes tertbutyloxycarbonyl-N-methyl D-leucine (Boc-N-Me-D-Leu-OH)
Tertbutyloxycarbonyl-D-Leu (20mol, 4.62g) that embodiment 2 is obtained be dissolved in oxolane (THF,
100mL) in solution, add iodomethane (100mol, 6.3mL) and sodium hydride (60mol, 2.4g), react 1-2 days, under ice-water bath
Add ethyl acetate (100mL) and water (20mL) to reaction system, remove organic solvent under reduced pressure, the anhydrous second of the aqueous solution obtained
Ether (60mL) and water (100mL) wash twice, and merge aqueous phase and are acidified to pH=2～3 with hydrochloric acid under ice-water bath, and ethyl acetate extracts
Take (100mL × 3), merge organic facies, the most respectively with water (150mL), 5%Na2S2O3Aqueous solution (100mL × 3) and saturated food
Saline (100mL) washs, and anhydrous sodium sulfate is dried, and filters, solvent is evaporated off, and oil pump is dried, and obtains clear oil thing tertiary butyloxycarbonyl
Base-N-methyl D-leucine, productivity 89.2%.Embodiment 5 synthesizes tertbutyloxycarbonyl-N-methyl D-phenylalanine (Boc-N-
Me-D-Phe-OH)
Repeat the operation of embodiment 4, except that the tertbutyloxycarbonyl-D-phenylalanine replacement obtained by embodiment 3
Tertbutyloxycarbonyl-D-Leu, thus prepare clear oil thing tertbutyloxycarbonyl-N-methyl D-phenylalanine, productivity
87.2%.
Embodiment 6 synthesizes Boc-N-Me-D-Leu-D-Leu-OBn
Under nitrogen protection, the Boc-N-Me-D-Leu-OH1.47g that Example 4 obtains is dissolved in 10mL THF, ice-water bath
Under be sequentially added into 2.70g DEPBT and 1.6ml DIEA, after reaction 10min, add 2.60g D-Leu benzyl ester to toluene sulphur
Hydrochlorate, to be dissolved after with DIEA regulate pH=7～8, naturally be warmed to room temperature, be stirred overnight, TLC follow the tracks of reaction to raw material point disappearance
After, remove solvent, silica gel column chromatography (eluant V under reduced pressurePetroleum ether: VAcetone=25:1), obtain white crystalline tertbutyloxycarbonyl-N-
Two PEPDs are protected at methyl-D-leucyl-D-Leu benzyl ester two ends1(Boc-N-Me-D-Leu-D-Leu-OBn) 2.52g, yield
It is 93.6%.
Embodiment 7 synthesizes Boc-N-Me-D-Phe-D-Leu-OBn
Under nitrogen protection, the Boc-N-Me-D-Phe-OH1.67g that Example 5 obtains is dissolved in 10mL THF, ice-water bath
Under be sequentially added into 2.70g DEPBT and 1.6ml DIEA, after reaction 10min, add 2.60g D-Leu benzyl ester to toluene sulphur
Hydrochlorate, to be dissolved after with DIEA regulate pH=7～8, naturally be warmed to room temperature, be stirred overnight, TLC follow the tracks of reaction to raw material point disappearance
After, remove solvent, silica gel column chromatography (eluant V under reduced pressurePetroleum ether: VAcetone=25:1), obtain white crystalline tertbutyloxycarbonyl-N-
Two PEPDs are protected at methyl D-phenylalanyl-D-Leu benzyl ester two ends2(Boc-N-Me-D-Phe-D-Leu-OBn) 2.68g, receives
Rate is 92.5%.
Embodiment 8 synthesizes Boc-L-Leu-N-Me-D-Phe-D-Leu-OBn
The Boc-N-Me-D-Phe-D-Leu-OBn2.41g that Example 7 obtains is dissolved in 20mL CH2Cl2In, nitrogen is protected
Lower addition 1.05ml methyl phenyl ethers anisole, stirs under ice bath, drips 5ml TFA, after reacting 4 hours, removes solvent under reduced pressure, add 20mL
CH2Cl2, remove under reduced pressure, three removing TFA of repetitive operation, the N-methyl of oil pump drying to obtain removing tertbutyloxycarbonyl protection-
D-phenylalanyl-D-Leu benzyl ester (H-N-Me-D-Phe-D-Leu-OBn), is dissolved in 5mL THF standby, and nitrogen is protected
Under, 1.67g embodiment 1 is obtained Boc-L-Leu-OH and is dissolved in 10mL THF, be sequentially added under ice-water bath 2.24g DEPBT and
1.3ml DIEA, after reaction 10min, adds standby H-N-Me-D-Phe-D-Leu-OBn THF solution, regulates pH with DIEA
=7～8, naturally it is warmed to room temperature, is stirred overnight, follow the tracks of with TLC and react to the disappearance of raw material point, remove solvent, silicagel column under reduced pressure
Chromatography (eluant VPetroleum ether: VAcetone=25:1), obtain clear oil tertbutyloxycarbonyl-L-leucyl-N-methyl D-phenylalanyl-
D-Leu benzyl ester two ends protection tripeptides T (Boc-L-Leu-N-Me-D-Phe-D-Leu-OBn) 2.56g, two step yields are
85.3%.
Embodiment 9 synthesizes Boc-L-Leu-N-Me-D-Phe-D-Leu-N-Me-D-Leu-D-Leu-OBn
Protection two PEPD that Example 6 obtains12.24g, removes tertbutyloxycarbonyl protection by embodiment 8, obtains N-first
Base-D-leucyl-D-Leu benzyl ester (H-N-Me-D-Leu-D-Leu-OBn) to be dissolved in 5mL THF standby；Treating excess syndrome is executed
The protection tripeptides T2.38g that example 8 obtains is dissolved in 20mL ethyl acetate, adds 0.8g10%Pd/C, airtight condition under nitrogen protection
Under be passed through the hydrogen reducing that pressure is 0.1MPa, under room temperature stirring reaction, TLC follow the tracks of, react 4～6 hours, stopping be passed through hydrogen
Gas, filters, removes solvent under reduced pressure, is dried, and obtains removing the tertbutyloxycarbonyl-L-leucyl-N-methyl D-phenylpropyl alcohol of benzyl protection
Aminoacyl-D-Leu (Boc-L-Leu-N-Me-D-Phe-D-Leu-OH)；Under nitrogen protection, the Boc-L-Leu-N-that will obtain
Me-D-Phe-D-Leu-OH is dissolved in 10mL THF, is sequentially added into 1.80g DEPBT and 1.1ml DIEA under ice-water bath, reaction
After 10min, add standby H-N-Me-D-Leu-D-Leu-OBn THF solution, regulate pH=7～8 with DIEA, naturally rise to
Room temperature, is stirred overnight, and follows the tracks of with TLC and reacts to the disappearance of raw material point, removes solvent, silica gel column chromatography (eluant V under reduced pressurePetroleum ether:
VAcetone=25:1), obtain clear oil two ends protection line style pentapeptide (Boc-L-Leu-N-Me-D-Phe-D-Leu-N-Me-D-
Leu-D-Leu-OBn) 2.72g, three step yields are 81.4%.
Embodiment 10 synthesizes cyclo-(N-Me-D-Phe-D-Leu-N-Me-D-Leu-D-Leu-L-Leu)
The two ends that Example 9 obtains protect linear pentapeptide 0.4277g to be dissolved in 8mL CH2Cl2In, nitrogen protection is lower to add
0.1ml methyl phenyl ethers anisole, stirs under ice bath, is slowly added dropwise 2ml TFA, after reacting 4 hours, removes solvent under reduced pressure, add 10mL
CH2Cl2, removing under reduced pressure, repetitive operation removes TFA, linear the five of oil pump drying to obtain removing tertbutyloxycarbonyl protection for three times
Peptide；The linear pentapeptide of removing tertbutyloxycarbonyl protection is dissolved in 10mL ethyl acetate, under nitrogen protection, adds 0.14g10%
Pd/C, is passed through the hydrogen reducing that pressure is 0.1MPa under airtight condition, stirring reaction under room temperature, and TLC follows the tracks of, and reaction 4～6 is little
Time, stop being passed through hydrogen, filter, remove solvent under reduced pressure, be dried, i.e. obtain removing the linear pentapeptide of benzyl protection；By above-mentioned de-
Except the linear pentapeptide of benzyl protection is dissolved in the THF-CH that 120mL volume ratio is 2:1:22Cl2-CH3In CN mixed solution, under room temperature
Nitrogen is protected, and is sequentially added into 0.1426gHATU, 0.1122g DEPBT and 0.1204g TBTU, successive reaction 4～6 days, decompression
Solvent is evaporated off, uses CH2Cl2Saturated NaHCO is used successively after dissolving3Aqueous solution and water washing, anhydrous MgSO4It is dried, concentrates, with anti-
Phase HPLC (Agilent Eclipse ZORBAX SB-C18,5 μm, 9.4 × 250nm) isolated white needles ring pentapeptide is brilliant
Body cyclo-(N-Me-D-Phe-D-Leu-N-Me-D-Leu-D-Leu-L-Leu) 205.6mg, productivity 65.5%, purity reaches
More than 99%.The structural characterization data of products therefrom are as follows, confirm as structural formula compound ring as follows (N-methyl D-
Phenylalanyl-D-leucyl-N-methyl-D-leucyl-D-leucyl-L-leucyl):
1H-NMR (500MHZ, CDCl3), δ (ppm):
7.89 (s, 1H), 7.21 (m, 5H), 6.70 (m, 1H), 5.53 (m, 1H), 5.09 (m, 1H), 4.82 (d, J=
10.0Hz, 1H), 4.77 (m, 1H), 4.31 (m, 1H), 3.67 (dd, J=5.0Hz, 5.0Hz, 1H), 3.56 (ddd, J=
5.0Hz, 5.0Hz, 5.0Hz, 1H), 3.34 (m, 1H), 3.13 (m, 2H), 2.98 (m, 2H), 2.81 (m, 1H), 2.68 (d, J=
5.0Hz, 1H), 2.27 (m, 1H), 1.85 (m, 4H), 1.55 (m, 7H), 0.90 (m, 18H), 0.70 (m, 6H)；
13C-NMR (125MHZ, CDCl3), δ (ppm):
173.4,172.9,172.1,171.4,168.5,138.8,129.5 (2C), 128.8,128.7,127,68.36
(2C), 59.37,55.37,47.66,47.3,41.7,36.0 (3C), 30.8 (2C), 25.4 (3C), 23.0 (3C), 22.6
(3C), 22.03 (C).
Embodiment 11 cell is cultivated
The tumor cell line of the present invention includes HepG2 cell lines, human colon cancer cell strain SW480, brain colloid
Tumor cell strain U87, human breast cancer cell line Bcap-37 and human normal liver cell L 02.Culture medium (DMEM) is added hyclone
(FBS, 10%), streptomycin and penicillin dual anti-(1%).Condition of culture: 37 DEG C, 5%CO2；Relative humidity: 95%.
(1) experiment pre-treatment: the required consumptive material after every high pressure is placed in superclean bench, sprays with ethanol watering can
Experiment table top, and close work light and open and start experimental implementation after ultra violet lamp 30min；
(2) recovery cell: cryopreservation tube is taken out from liquid nitrogen, puts in 37 DEG C of water-baths, gentle agitation immediately.Liquid
After all melting, take out specking 75% ethanol and be placed in superclean bench.Then cell suspending liquid is drawn onto in 15mL centrifuge tube,
By culture medium, cryopreservation tube being washed one time, the cell sticked on wall all is washed, add 5mL culture medium, 2000 leave 3 points of the heart
Clock.Then abandon supernatant, add 1mL culture medium suspension cell, be drawn onto equipped with in the 7.5cm plastic culture bottle of 5mL culture medium, front and back
Left and right is shaken gently for, and makes the cell in culture bottle be uniformly distributed.Finally mark cell category, date and cultivation people etc., be placed on CO2
Cultivating in incubator, every day, observation of cell growing state, changed culture medium according to its growth conditions, when cell growth state is steady
Fixed, and during in exponential phase, can be used for testing.
Embodiment 12 anti tumor activity in vitro is studied
Ring pentapeptide and Galaxamide use mtt assay to study its anti tumor activity in vitro, and concrete operation step is:
(1) inoculating cell: collect logarithmic (log) phase cell, adjusts concentration of cell suspension, connects with every hole 1000～10000 cells
Plant in 96 orifice plates, every pore volume 100 μ l (edge hole is filled with aseptic PBS)；
(2) cell is cultivated: at 5%CO2, the cell culture incubator of 37 DEG C to be hatched, dosing in morning next day, every hole adds 100 μ
The sample to be tested of l variable concentrations, if 5 multiple holes；
(3) colour generation: cultivate 72 hours, every hole adds 20 μ l MTT solution (5mg/mL prepares with PBS, pH=7.4), continues
Continuous 4h of hatching, termination is cultivated, and carefully inhales and abandons culture supernatant in hole, and every hole adds 150 μ l DMSO, and decolorization swinging table vibrates
10min, makes crystal fully dissolve；
(4) colorimetric: select 570nm wavelength, measures the absorbance in each hole in microplate reader, records result, calculates cell
Survival rate, and try to achieve half-inhibition concentration (IC50/μg/mL)。
Table 1 anti tumor activity in vitro is tested
| HepG2 | SW480 | U87 | MCF-7 | L02 | |
| Galaxamide | 4.63 | 43.82 | 10.61 | 14.09 | 60.08 |
| PX | 1.46 | 5.1 | 1.85 | 4.18 | 50.68 |
Mtt assay is used to have studied ring pentapeptide and the anti tumor activity in vitro of Galaxamide of the present invention, result such as table 1 institute
Show.HepG2 cell lines, human colon cancer cell strain SW480, brain glioblastoma cell strain U87, human breast cancer cell are selected
MCF-7 and a kind of Human normal hepatocyte strain L02 studies their activity, and drug treating time is all 72h.Can from table
Going out, hepatoma H22 cells, human colon cancer cell strain SW480, brain glioblastoma cell strain U87 are had by the ring pentapeptide of the present invention
Good inhibiting effect, its IC50Value is respectively 1.46 μ g/mL, 5.1 μ g/mL and 1.85 μ g/mL；Resisting of the ring pentapeptide of the present invention
Tumor promotion is more preferable than Galaxamide, and both are more much smaller than tumor cell to the toxicity of normal cell L02；The present invention's
Ring pentapeptide demonstrates preferable selectivity to normal cell and tumor cell, illustrates good in terms of the treatment and prevention of tumor
Application prospect.
Embodiment 13 is apoptotic measures research
The cyclic pentapeptide compound research to HepG 2 cell apoptosis mode, it is characterised in that use
Annexin V-FITC/PI double dye method detection apoptosis, it is thin that this method can distinguish living cells, viable apoptotic cell and death
Born of the same parents.Its concrete operation step is as follows:
(1) inoculating cell: collect logarithmic (log) phase cell, adjusts concentration of cell suspension, is inoculated into 1000000, every hole cell
In 6 orifice plates, every pore volume 2mL；
(2) cell is cultivated: at 5%CO2, the cell culture incubator of 37 DEG C to be hatched, dosing in morning next day, every hole adds 1mL
The sample to be tested of variable concentrations, cultivates 72 hours；
(3) collecting cell, including the cell swum in culture medium, 2000 leave the heart 5 minutes, abandon supernatant, use 1mL PBS
Resuspended sample presentation, normal components cell separates 200 μ l volumes and does not dyes；
(4) centrifugal: 1000 revs/min, 5min, abandons supernatant；
(5) resuspended: to add 200 μ l Binding Buffer buffer mixings；
(6) dyeing: adding 5 μ l Annexin V-FITC, room temperature lucifuge hatches 10 minutes；
(7) centrifugal: 1000 revs/min, 5min, abandons supernatant；
(8) resuspended: to add 200 μ l Binding Buffer buffer mixings；
(9) dyeing: add 5 μ l PI, directly use flow cytometer measurement result.
Measured result is as in figure 2 it is shown, result shows, along with the increase of drug level, apoptosis rate is also gradually increased.This
Outward, energy force rate Galaxamide of the ring pentapeptide inducing cell apoptosis of the present invention is higher, under same concentrations, and the ring pentapeptide of the present invention
Effect higher.Result shows, the ring pentapeptide of the present invention has the ability of more preferable inducing cell apoptosis.
Above-described embodiment is the present invention preferably embodiment, but embodiments of the present invention are not by above-described embodiment
Limit, the change made under other any spirit without departing from the present invention and principle, modify, substitute, combine, simplify,
All should be the substitute mode of equivalence, within being included in protection scope of the present invention.
Claims (7)
1. the synthetic method of a ring pentapeptide, it is characterised in that described ring pentapeptide has a following structural formula:
Described synthetic method includes following synthesis step:
(1) L-Leu, D-Leu and D-phenylalanine are carried out with Bis(tert-butoxycarbonyl)oxide respectively aminoterminal protection reaction,
Respectively obtain tertbutyloxycarbonyl-L-Leu, tertbutyloxycarbonyl-D-Leu and tertbutyloxycarbonyl-D-phenylalanine；
(2) tertbutyloxycarbonyl-D-Leu step (1) obtained and tertbutyloxycarbonyl-D-phenylalanine respectively with iodomethane
Carry out methylation reaction, respectively obtain tertbutyloxycarbonyl-N-methyl D-leucine and tertbutyloxycarbonyl-N-methyl D-phenylpropyl alcohol ammonia
Acid；
(3) tertbutyloxycarbonyl-N-methyl D-leucine step (2) obtained and tertbutyloxycarbonyl-N-methyl D-phenylpropyl alcohol ammonia
Acid carries out condensation reaction with D-Leu benzyl ester tosilate respectively, obtain tertbutyloxycarbonyl-N-methyl-D-leucyl-
Two PEPDs are protected at D-Leu benzyl ester two ends1With tertbutyloxycarbonyl-N-methyl D-phenylalanyl-D-Leu benzyl ester two ends protection
Two PEPDs2；
(4) two PEPDs that step (3) is obtained2After removing tertbutyloxycarbonyl protection, the tertbutyloxycarbonyl-L-obtained with step (1)
Leucine carries out condensation reaction and obtains tertbutyloxycarbonyl-L-leucyl-N-methyl D-phenylalanyl-D-Leu benzyl ester two ends
Protection tripeptides T；
(5) two PEPDs that step (3) is obtained1Removing tertbutyloxycarbonyl protection, tripeptides T step (4) obtained removing benzyl is protected
Protect, then both are carried out condensation reaction obtain tertbutyloxycarbonyl-L-leucyl-N-methyl D-phenylalanyl-D-leucyl-
N-methyl-D-leucyl-D-Leu benzyl ester two ends protection line style pentapeptide；
(6) the linear pentapeptide that step (5) obtains is removed respectively tertbutyloxycarbonyl protection and benzyl protection, at mixing condensation reagent
Effect under carry out ring-closure reaction and i.e. obtain target product ring (N-methyl D-phenylalanyl-D-leucyl-N-methyl D-bright ammonia
Acyl-D-leucyl-L-leucyl) pentapeptide.
The synthetic method of a kind of ring pentapeptide the most according to claim 1, it is characterised in that: aminoterminal described in step (1)
The concrete operation step of protection reaction is: under nitrogen protection, be sequentially added into oxolane, H in round-bottomed flask2O and
1.0mol/L NaOH solution, ice-water bath cooling disposably adds L-Leu, D-Leu or D-phenylalanine, stirs molten
Solving uniformly, the most disposably add Bis(tert-butoxycarbonyl)oxide, be warmed to room temperature after continuing stirring 10min under ice-water bath, regulation pH is
10～10.5, it is stirred overnight, after removing solvent under reduced pressure, extracts with absolute ether, aqueous phase cools down under ice-water bath and uses 1mol/L
Hydrochloric acid is acidified to pH=2, is then extracted with ethyl acetate 3 times, merges organic facies and washs with saturated aqueous common salt, anhydrous MgSO4
Dried filtration, finally steams solvent, respectively obtains tertbutyloxycarbonyl-L-Leu, tertbutyloxycarbonyl-D-Leu or tertiary fourth
Oxygen carbonyl-D-phenylalanine.
The synthetic method of a kind of ring pentapeptide the most according to claim 1, it is characterised in that: step methylates described in (2)
The concrete operation step of reaction is: tertbutyloxycarbonyl-D-Leu or tertbutyloxycarbonyl-D-phenylalanine are dissolved in oxolane
In solution, adding iodomethane and sodium hydride, react 1-2 days, ice-water bath downhill reaction system adds ethyl acetate and water, and decompression is steamed
Except organic solvent, the aqueous solution absolute ether obtained and water wash twice, and merge aqueous phase and are acidified to hydrochloric acid under ice-water bath
PH=2～3, ethyl acetate extracts 3 times, merges organic facies, the most respectively with water, mass fraction 5%Na2S2O3Aqueous solution is with full
And brine It, anhydrous sodium sulfate is dried, filter, solvent is evaporated off, oil pump is dried, respectively obtain tertbutyloxycarbonyl-N-methyl-
D-Leu or tertbutyloxycarbonyl-N-methyl D-phenylalanine.
The synthetic method of a kind of ring pentapeptide the most according to claim 1, it is characterised in that: institute in step (3), (4), (5)
State condensation reaction to refer in condensation reagent 3-(diethoxy phosphoryl oxy)-1,2,3-phentriazine-4-ketone and diisopropyl second
Treating that condensation substance carries out dehydrating condensation accordingly for two kinds in the presence of amine, its concrete operation step is: under nitrogen protection, by tertiary fourth
Oxygen carbonyl-protection treat that condensation substance is dissolved in oxolane, be sequentially added into 3-(diethoxy phosphoryl oxy)-1 under ice-water bath, 2,
3-phentriazine-4-ketone and diisopropylethylamine, add benzyl protection compound after reaction 10～15min, to be dissolved rear with two
Wopropyl ethyl amine regulation pH is 7～8, naturally is warmed to room temperature, is stirred overnight, with thin layer chromatography TLC detection consumption of raw materials complete after,
Remove solvent, silica gel column chromatography under reduced pressure, obtain condensation product.
The synthetic method of a kind of ring pentapeptide the most according to claim 1, it is characterised in that: institute in step (4), (5), (6)
State removing tertbutyloxycarbonyl protection to refer to remove in the mixed liquor of the trifluoroacetic acid that volume ratio is 1:4 and dichloromethane treat accordingly
Tertbutyloxycarbonyl in de-thing, its concrete operation step is: be dissolved in dichloromethane by the thing to be taken off that tertbutyloxycarbonyl is protected, nitrogen
Add methyl phenyl ethers anisole under gas shielded, stir under ice bath, drip trifluoroacetic acid, after reacting 4～6 hours, remove solvent under reduced pressure, add
Dichloromethane, removes under reduced pressure, and repetitive operation removes trifluoroacetic acid for three times, oil pump drying to obtain removing tertbutyloxycarbonyl protection
Product.
The synthetic method of a kind of ring pentapeptide the most according to claim 1, it is characterised in that: de-described in step (5), (6)
Except benzyl protection refers to remove the benzyl in thing to be taken off with the Pd/C hydrogenolysis reducing that the weight/mass percentage composition of palladium is 10%, its
Concrete operation step is: be dissolved in ethyl acetate by the thing to be taken off of benzyl protection, adds material amount 1/3 to be taken off under nitrogen protection
10%Pd/C, is passed through the hydrogen reducing that pressure is 0.1Mpa under air-proof condition, stirring reaction under room temperature, and TLC follows the tracks of, and reacts 4～6
Hour, stop being passed through hydrogen, filter, reclaim Pd/C, remove solvent under reduced pressure, be dried, i.e. obtain removing the product of benzyl protection.
The synthetic method of a kind of ring pentapeptide the most according to claim 1, it is characterised in that: described in step (6), cyclization is anti-
Should refer at O-BTA-N, N, N', N'-tetramethylurea Tetrafluoroboric acid ester, 2-(7-azo BTA)-N, N,
N', N'-tetramethylurea hexafluorophosphoric acid ester, 3-(diethoxy phosphoryl oxy)-1,2,3-phentriazine-4-ketone and diisopropyl second
Carrying out cyclization in the presence of amine, its concrete operation step is: by removing tertbutyloxycarbonyl protection and the linear pentapeptide of benzyl protection
It is dissolved in the THF-CH that volume ratio is 2:1:22Cl2-CH3In CN mixed solution, ambient temperature under nitrogen is protected, and is sequentially added into 2-(7-azo
BTA)-N, N, N', N'-tetramethylurea hexafluorophosphoric acid ester, 3-(diethoxy phosphoryl oxy)-1,2,3-phentriazines-
4-ketone and O-BTA-N, N, N', N'-tetramethylurea Tetrafluoroboric acid ester, successive reaction 4～6 days, remove solvent under reduced pressure,
Use CH2Cl2Saturated NaHCO is used successively after dissolving3Aqueous solution and water washing, anhydrous MgSO4It is dried, concentrates, separate with reversed-phase HPLC
Obtain ring five peptide prod.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410168828.8A CN103965299B (en) | 2014-04-24 | 2014-04-24 | A kind of ring pentapeptide and synthetic method thereof and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410168828.8A CN103965299B (en) | 2014-04-24 | 2014-04-24 | A kind of ring pentapeptide and synthetic method thereof and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103965299A CN103965299A (en) | 2014-08-06 |
| CN103965299B true CN103965299B (en) | 2016-07-13 |
Family
ID=51235347
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410168828.8A Active CN103965299B (en) | 2014-04-24 | 2014-04-24 | A kind of ring pentapeptide and synthetic method thereof and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103965299B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106188231B (en) * | 2015-05-25 | 2021-10-22 | 中国医学科学院药物研究所 | Synthesis and application of pasireotide pentapeptide intermediate |
| CN108101811A (en) | 2016-11-25 | 2018-06-01 | 斯福瑞（南通）制药有限公司 | The method for producing N- tertbutyloxycarbonyl -2- amino -3,3- acid dimethyls |
| CN107936084A (en) * | 2017-11-01 | 2018-04-20 | 十堰市太和医院 | A kind of production method for the CAP23145 polypeptides based on targeting FMRP for treating glioma |
| CN113667079A (en) * | 2021-07-19 | 2021-11-19 | 江苏师范大学 | Preparation method of carbon-carbon double bond bridged chiral porous organic polymer |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101270154A (en) * | 2008-05-09 | 2008-09-24 | 暨南大学 | Cyclo-pentapeptide with antineoplastic activity |
| CN101270153A (en) * | 2008-05-09 | 2008-09-24 | 暨南大学 | Cyclo-pentapeptide and synthesizing method |
| CN102329376A (en) * | 2011-07-07 | 2012-01-25 | 暨南大学 | Cyclo(phenylalanine-N-methylleucyl-leucyl-N-methylleucyl-leucyl), and synthesis method and application thereof |
-
2014
- 2014-04-24 CN CN201410168828.8A patent/CN103965299B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101270154A (en) * | 2008-05-09 | 2008-09-24 | 暨南大学 | Cyclo-pentapeptide with antineoplastic activity |
| CN101270153A (en) * | 2008-05-09 | 2008-09-24 | 暨南大学 | Cyclo-pentapeptide and synthesizing method |
| CN102329376A (en) * | 2011-07-07 | 2012-01-25 | 暨南大学 | Cyclo(phenylalanine-N-methylleucyl-leucyl-N-methylleucyl-leucyl), and synthesis method and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| Paper Synthesis, Cytotoxicity and Apoptosis Induction in Human Tumor Cells by Galaxamide and Its Analogues;Xiao X.等;《Mar. Drugs》;20140818(第12期);全文 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103965299A (en) | 2014-08-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106349148B (en) | New indole class compound with anti-tumor metastasis and anti-inflammatory activity, synthesis and application | |
| CN103159828B (en) | 1-(4-hydroxy-3-methoxycarbonyl)-beta-carboline-3-formyl tryptophyl amino acid benzyl ester, and synthesis and application thereof | |
| CN103965299B (en) | A kind of ring pentapeptide and synthetic method thereof and application | |
| CN100427502C (en) | Antineoplastic oligopeptide and its preparation method and application | |
| CN106177977A (en) | A kind of antitumor drug ternary conjugate and synthesis and application | |
| CN102250203B (en) | Beta-carboline aminoacid benzyl ester, preparation method and application thereof | |
| CN101337985A (en) | Self-assembly short peptides constructed by D type amino acid, use for nano-biomedicine | |
| CN105218637A (en) | The indoles quinolizine that LPNISKP modifies, its preparation, nanostructure, active and application | |
| CN109678987A (en) | A kind of hydrogen sulfide releasing agent HA-ADT, preparation method and application | |
| CN106349244B (en) | Benzimidazole and quinazoline dimethoxy-benzene oxygen acetyl-AA-OBzl, synthesis, activity and application | |
| CN103374056A (en) | 1-Acetyl-beta-carboline-3-formyl amino-acid benzyl ester, and synthesis and application thereof | |
| CN108395429A (en) | A kind of compound and its preparation method and application | |
| CN104817568A (en) | 5, 6-bidehydronorcantharides alcohol derivative and application thereof to tumor resistance | |
| CN116251195B (en) | Paclitaxel targeting peptide conjugate and application thereof | |
| CN110240631A (en) | Chiral isoindolone and cyclic hexapeptide derivatives, its preparation method and purposes | |
| CN110522923A (en) | The matrix material of fructose and the co-modified dual-target triple negative breast cancer of RGD peptide | |
| CN112940059B (en) | Glycosyl modified naphthalimide-polyamine conjugate, preparation method and application thereof | |
| CN105121447A (en) | Vinblastine derivatives, preparation method therefor and application thereof | |
| CN111943947B (en) | 1H-pyrrole [2,3-b ] pyridine derivative and synthesis method and application thereof | |
| CN106146584B (en) | Novel cytidine derivatives dimer and its application | |
| CN113185582A (en) | Cyclic pentapeptide Galaxamide, preparation method thereof and application thereof in preparation of antitumor drugs | |
| CN105294836A (en) | LPNISKP modified 5-fluorouracil, preparation therefor, nanostructure thereof, activity thereof and application thereof | |
| CN105294835A (en) | LDV modified 5-fluorouracil, preparation therefor, nanostructure thereof, vigor thereof and application thereof | |
| CN109824642B (en) | Chrysin phenylalanine derivative with anti-lung cancer activity | |
| CN109734692B (en) | Chrysin leucine derivative with EGFR kinase inhibitory activity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |